Theratechnologies (THTX) Reports Q1 Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023
April 12, 2023 7:30 AM EDTQ1 2023 Consolidated Revenue Grew 7%, Supported by 9% Growth in EGRIFTA SV® Revenue and 5% Growth in Trogarzo® Revenue Revised Sudocetaxel Zendusortide (TH1902) Phase 1 Trial Protocol Expected to be Filed by End of April FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and... More
